OKT3 for treatment of rejection in renal transplantation

A. M. DeMattos, Douglas Norman

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

OKT3 is highly effective both as an initial treatment for renal allograft rejection and as a treatment for rejection episodes resistant to other agents. When compared both prospectively and retrospectively with high-dose steroids, OKT3 was reported to be more effective in the first-line treatment of renal allograft rejection. In a large multicenter randomized trial, OKT3 reversed rejection episodes in a significantly greater number of patients and produced significantly better 1-yr graft survival than did steroids. Both agents were associated with similar numbers of infections. Acute adverse reactions attributable to cytokine release followed initial doses of OKT3. In uncontrolled trials, OKT3 reversed 50% to 100% of steroid-resistant rejections; and in a comparative study, it reversed a greater number of steroid-resistant rejection episodes than did polyclonal antilymphocyte globulins. Successful First-line and second-line (steroid-resistant) OKT3 reversal of acute severe rejection has been shown to be associated with these factors: initiation of OKT3 therapy within 7 d of rejection diagnosis and cyclosporine levels above 150 ng/ml prior to initiation of treatment. Second-line treatment of steroid-resistant rejection also was shown to be most effective in histopathologically pure acute cellular rejection episodes (lacking interstitial fibrosis). As third-line therapy, OKT3 reversed rejection episodes in 74% to 84% of patients. It is unclear whether, during OKT3 treatment, cyclosporine should be discontinued to lessen its potential for nephrotoxicity and over-immunosuppression or its dosage reduced to maintain additional immunosuppression and suppression of anti-OKT3 antibody production. OKT3 has been successfully administered for the treatment of rejection on an outpatient basis, offering considerable cost savings over continued hospitalization.

Original languageEnglish (US)
Pages (from-to)374-381
Number of pages8
JournalClinical Transplantation
Volume7
Issue number4 II
StatePublished - 1993

Fingerprint

Muromonab-CD3
Kidney Transplantation
Steroids
Therapeutics
Immunosuppression
Cyclosporine
Allografts
Kidney
Peptide Initiation Factors
Antilymphocyte Serum
Cost Savings
Graft Survival
Multicenter Studies
Antibody Formation
Anti-Idiotypic Antibodies
Hospitalization
Fibrosis
Outpatients

Keywords

  • Immunosuppression
  • Kidney transplantation
  • Muromonab-CD3
  • OKT3

ASJC Scopus subject areas

  • Immunology
  • Transplantation

Cite this

OKT3 for treatment of rejection in renal transplantation. / DeMattos, A. M.; Norman, Douglas.

In: Clinical Transplantation, Vol. 7, No. 4 II, 1993, p. 374-381.

Research output: Contribution to journalArticle

@article{099b7b68d3de48368161222f4dd9c20c,
title = "OKT3 for treatment of rejection in renal transplantation",
abstract = "OKT3 is highly effective both as an initial treatment for renal allograft rejection and as a treatment for rejection episodes resistant to other agents. When compared both prospectively and retrospectively with high-dose steroids, OKT3 was reported to be more effective in the first-line treatment of renal allograft rejection. In a large multicenter randomized trial, OKT3 reversed rejection episodes in a significantly greater number of patients and produced significantly better 1-yr graft survival than did steroids. Both agents were associated with similar numbers of infections. Acute adverse reactions attributable to cytokine release followed initial doses of OKT3. In uncontrolled trials, OKT3 reversed 50{\%} to 100{\%} of steroid-resistant rejections; and in a comparative study, it reversed a greater number of steroid-resistant rejection episodes than did polyclonal antilymphocyte globulins. Successful First-line and second-line (steroid-resistant) OKT3 reversal of acute severe rejection has been shown to be associated with these factors: initiation of OKT3 therapy within 7 d of rejection diagnosis and cyclosporine levels above 150 ng/ml prior to initiation of treatment. Second-line treatment of steroid-resistant rejection also was shown to be most effective in histopathologically pure acute cellular rejection episodes (lacking interstitial fibrosis). As third-line therapy, OKT3 reversed rejection episodes in 74{\%} to 84{\%} of patients. It is unclear whether, during OKT3 treatment, cyclosporine should be discontinued to lessen its potential for nephrotoxicity and over-immunosuppression or its dosage reduced to maintain additional immunosuppression and suppression of anti-OKT3 antibody production. OKT3 has been successfully administered for the treatment of rejection on an outpatient basis, offering considerable cost savings over continued hospitalization.",
keywords = "Immunosuppression, Kidney transplantation, Muromonab-CD3, OKT3",
author = "DeMattos, {A. M.} and Douglas Norman",
year = "1993",
language = "English (US)",
volume = "7",
pages = "374--381",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "4 II",

}

TY - JOUR

T1 - OKT3 for treatment of rejection in renal transplantation

AU - DeMattos, A. M.

AU - Norman, Douglas

PY - 1993

Y1 - 1993

N2 - OKT3 is highly effective both as an initial treatment for renal allograft rejection and as a treatment for rejection episodes resistant to other agents. When compared both prospectively and retrospectively with high-dose steroids, OKT3 was reported to be more effective in the first-line treatment of renal allograft rejection. In a large multicenter randomized trial, OKT3 reversed rejection episodes in a significantly greater number of patients and produced significantly better 1-yr graft survival than did steroids. Both agents were associated with similar numbers of infections. Acute adverse reactions attributable to cytokine release followed initial doses of OKT3. In uncontrolled trials, OKT3 reversed 50% to 100% of steroid-resistant rejections; and in a comparative study, it reversed a greater number of steroid-resistant rejection episodes than did polyclonal antilymphocyte globulins. Successful First-line and second-line (steroid-resistant) OKT3 reversal of acute severe rejection has been shown to be associated with these factors: initiation of OKT3 therapy within 7 d of rejection diagnosis and cyclosporine levels above 150 ng/ml prior to initiation of treatment. Second-line treatment of steroid-resistant rejection also was shown to be most effective in histopathologically pure acute cellular rejection episodes (lacking interstitial fibrosis). As third-line therapy, OKT3 reversed rejection episodes in 74% to 84% of patients. It is unclear whether, during OKT3 treatment, cyclosporine should be discontinued to lessen its potential for nephrotoxicity and over-immunosuppression or its dosage reduced to maintain additional immunosuppression and suppression of anti-OKT3 antibody production. OKT3 has been successfully administered for the treatment of rejection on an outpatient basis, offering considerable cost savings over continued hospitalization.

AB - OKT3 is highly effective both as an initial treatment for renal allograft rejection and as a treatment for rejection episodes resistant to other agents. When compared both prospectively and retrospectively with high-dose steroids, OKT3 was reported to be more effective in the first-line treatment of renal allograft rejection. In a large multicenter randomized trial, OKT3 reversed rejection episodes in a significantly greater number of patients and produced significantly better 1-yr graft survival than did steroids. Both agents were associated with similar numbers of infections. Acute adverse reactions attributable to cytokine release followed initial doses of OKT3. In uncontrolled trials, OKT3 reversed 50% to 100% of steroid-resistant rejections; and in a comparative study, it reversed a greater number of steroid-resistant rejection episodes than did polyclonal antilymphocyte globulins. Successful First-line and second-line (steroid-resistant) OKT3 reversal of acute severe rejection has been shown to be associated with these factors: initiation of OKT3 therapy within 7 d of rejection diagnosis and cyclosporine levels above 150 ng/ml prior to initiation of treatment. Second-line treatment of steroid-resistant rejection also was shown to be most effective in histopathologically pure acute cellular rejection episodes (lacking interstitial fibrosis). As third-line therapy, OKT3 reversed rejection episodes in 74% to 84% of patients. It is unclear whether, during OKT3 treatment, cyclosporine should be discontinued to lessen its potential for nephrotoxicity and over-immunosuppression or its dosage reduced to maintain additional immunosuppression and suppression of anti-OKT3 antibody production. OKT3 has been successfully administered for the treatment of rejection on an outpatient basis, offering considerable cost savings over continued hospitalization.

KW - Immunosuppression

KW - Kidney transplantation

KW - Muromonab-CD3

KW - OKT3

UR - http://www.scopus.com/inward/record.url?scp=0027323925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027323925&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027323925

VL - 7

SP - 374

EP - 381

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 4 II

ER -